title: [Chronic allograft dysfunction: role of immunosuppressive treatment].
abstract: Renal transplantation is the treatment of choice for patients with end-stage renal disease. In recent years a major improvement has been observed in short-term graft survival, but there has been no corresponding improvement in long-term survival. Chronic allograft dysfunction (CAD) is an anatomical and clinical alteration that can lead to the loss of the transplanted organ without any specific cause. The pathogenesis of CAD, which still remains to be fully clarified, involves both immunological factors (acute rejection, subclincial rejection, HLA mismatches between donor and recipient, noncompliance, etc) and non-immunological factors (marginal donor ischemia/reperfusion injury, infection, cardiovascular risk factors, nephrotoxicity, etc). Immunosuppressive therapy represents one of the strategies for the prevention of CAD. The introduction into clinical practice of novel immunosuppressive agents with no or lower nephrotoxicity, like mycophenolate mofetile, rapamycin and everolimus, will make therapeutic strategies aimed at decreasing the incidence of CAD feasible.
authors.affiliation: U.O. di Nefrologia, Dialisi e Trapianto, Policlinico S. Orsola, Universita' degli Studi, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Comai
authors.forename: G
authors.initials: G
authors.lastname: La Manna
authors.forename: G
authors.initials: G
authors.lastname: Feliciangeli
authors.forename: G
authors.initials: G
authors.lastname: Liviano D'Arcangelo
authors.forename: A
authors.initials: A
authors.lastname: Ferri
authors.forename: G
authors.initials: G
authors.lastname: Ubaldi
authors.forename: M P
authors.initials: MP
authors.lastname: Scolari
authors.forename: S
authors.initials: S
authors.lastname: Stefoni
mesh_terms: D002908:Chronic Disease; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000209:etiology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus